Design and synthesis of new trehalose-conjugated pentapeptides as inhibitors of Aβ(1-42) fibrillogenesis and toxicity

Journal of Peptide Science

Volumn 15, Issue 3, 2009, Pages 220-228

  De Bona, Paolo ^a   Giuffrida, Maria Laura ^a   Caraci, Filippo ^a   Copani, Agata ^a,b   Pignataro, Bruno ^c   Attanasio, Francesco ^b   Cataldo, Sebastiano ^c   Pappalardo, Giuseppe ^b   Rizzarelli, Enrico ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

sheet breaker peptides; Amyloid ; Neuronal cultures; SFM; Thioflavin T; Trehalose

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PENTAPEPTIDE; PEPTIDE; TREHALOSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; RAT; ANIMAL; ATOMIC FORCE MICROSCOPY; BRAIN CORTEX; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; SYNTHESIS;

RATTUS;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MASS SPECTROMETRY; MICROSCOPY, ATOMIC FORCE; PEPTIDES; RATS; TREHALOSE;

EID: 63449141261     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1109     Document Type: Article

References (32)

1. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
2. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 1993; 13: 1676-1687.
3. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D, Dobeli H. The toxicity of the Alzheimer's β-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 1997; 119: 59-71.
4. Simmons LK, May PC, Tommaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN. Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 1994; 45: 373-379.
5. Standridge JB. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. Curr. Alzheimer Res. 2006; 3: 95-108.
6. McLean CA, Chemy RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999; 46: 860-866.
7. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007; 27: 2866-2875.
8. Sciarretta KL, Gordon DJ, Meredith Sc. Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 2006; 413: 273-312.
9. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996; 271: 8545-8548.
10. Gibson TJ, Murphy RM. Design of peptidyl compounds that affect β-amyloid aggregation: Importance of surface tension and context. Biochemestry 2005; 44: 8898-8907.
11. Findeis MA, Lee J-D, Kelley M, Wakefield JD, Zhang M-H, Chin J, Kubasek W, Molineaux SM. Characterization of cholyl-leu-val-phephe-ala-OH as an inhibitor of amyloid beta-peptide polymerization. Amyloid 2001; 8: 231-241.
12. Hughes E, Burke RM, Doig AJ. Inhibition of toxicity in the peptide fragment β-(25-35) using N-methylated derivatives. A general strategy to prevent amyloid formation. J. Biol. Chem. 2000; 275: 25209-25115.
13. Gordon DJ, Tappe R, Meredith SC. Design and characterization of a membrane permeable N-methyl amino acid containing peptide that inhibits Aβ1-40 fibrillogenesis. J. Pept. Res. 2002; 60: 37-55.
14. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. 1996; 226: 672-680.
15. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard M-J, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with β-sheet breaker peptide. FASEB J. 2002; 16: 860-862.
16. Chacon MA, Barria MI, Soto C, Inestrosa NC. β-sheet breaker peptide prevents Aβ-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry 2004; 9: 953-961.
17. Adessi C, Frossard M-J, Boissard C, Fraga S, Bieler S, Ruckle T, Vilbois F, Robinson SM, Mutter M, Banks WA, Soto C. Pharmacological profile of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 2003; 278: 13905-13911.
18. Nitz M, Fenili D, Darabie AA, Wu L, Cousins JE, McLaurin J. Modulation of amyloid-β aggregation and toxicity by inosose stereoisomers. FEBS J. 2008; 275: 1663-1674.
19. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 2005; 20: 74-81.
20. Cucinotta V, Giuffrida A, Maccarrone G, Messina M, Puglisi A, Vecchio G. Synthesis and NMR characterization of β-alanine-bridged hemispherodextrin, a very efficient chiral selector in EKC. Electroforesis 2007; 28: 2580-2588.
21. Kates SA, Solè NA, Johnson CR, Hudson D, Barany G, Albericio F. A novel, convenient, three-dimensional orthogonal strategy for solid-phase synthesis of cyclic peptides. Tetrahedron Lett. 1993; 34: 1549-1552.
22. O'Nuallain B, Thakur AK, Williams AD, Bhattachatyya AM, Chen S, Thiagarajan G, Wetzel R. Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. Methods Enzymol. 2006; 43: 34-74.
23. Zagorski MG, Yang J, Shao H, Ma K, Zeng H, Hong A. Methodological and chemical factors affecting amyloi-β amyloidogenicity. Methods Enzymol. 1999; 309: 189-204.
24. Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorimetric determination of amyloid fibrils in vitro using the fluorescence dye, thioflavine T. Anal. Biochem. 1989; 177: 244-249.
25. LeVine H III. Quantification of beta-sheet amyloid fibril structures with thioflavine T. Methods Enzymol. 1999; 309: 274-284.
26. Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, Giuffrida Stella AM, Canonico PL, Nicoletti F, Sortino MA. Mitotic signaling by beta-amyloid causes neuronal death. FASEB J. 1999; 13: 2225-2234.
27. Pignataro B, Sardone L, Marletta G. Dynamic scanning force microscopy investigation of nanostructured spiral-like domains in Langmuir-Blodgettmonolayers. Nanotechnology 2003; 14: 245-249.
28. Tilstra L, Mattice WL. The β sheet = coil transition of polypeptides, as determined by circular dichroism. In Circular Dichroism and the Conformational Analysis of Biomolecules, Fasman GD (ed.). Plenum Press: New York and London, 1996; 261-283.
29. Blackley HK, Sanders GH, Davies MC, Roberts CJ, Tendler SJ, Wilkinson MJ. In-situ atomic force microscopy study of beta-amyloid fibrillization. J. Mol. Biol. 2000; 298: 833-840.
30. Arimon M, Díez-Péerez I, Kogan MJ, Durany N, Giralt E, Sanz F, Fernàndez-Busquets X. Fine structure study ofAβ1-42 fibrillogenesis with atomic forcemicroscopy. FASEB J. 2005; 19: 1344-1346.
31. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P. Cyclohexanehoxol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mousemodel. Nat. Med. 2006; 12: 801-808.
32. Laczko I, Vass E, Soòs K, Fulop L, Zarandi M, Penke B. Aggregation of Abeta(1-42) in the presence of short peptides: conformational studies. J. Pept. Sci. 2008; 14: 731-741.